Patient self-management of anticoagulants reduced arterial thromboembolism and adverse effects

Schulman, Sam
July 2005
ACP Journal Club;Jul/Aug2005, Vol. 143 Issue 1, p21
Academic Journal
This article focuses on a study related to comparing self-management of oral anticoagulant therapy with clinic management. Patient self-management of oral anticoagulants resulted in similar levels of control and major bleeding and lower rates of arterial thromboembolism and death than clinic-based management. Overall, anticoagulation self-monitoring provides international normalized ratios control that is as good as, or better than, that by a conventional laboratory, is convenient for patients, and may decrease adverse outcomes.


Related Articles

  • Acute Budd-Chiari Syndrome Associated with Activated Protein C Resistance During Intravenous Anticoagulant Treatment. Yildiz, B�lent O.; Oran, Bet�l; B�y�kasik, Yahya; Haznedaroglu, Ibrahim C.; �ekirge, Saruhan; Kirazli, Serafettin // Clinical & Applied Thrombosis/Hemostasis;Jul1998, Vol. 4 Issue 3, p220 

    The Budd-Chiari syndrome is a rare but serious condition defined as hepatic venous outflow obstruction. This article presents a case of acute Budd-Chiari syndrome in a 43-year-old woman with activated protein C resistance while she was being treated with intravenous heparin infusion for...

  • Stopping anticoagulant therapy after an unprovoked venous thromboembolism. Kearon, Clive // CMAJ: Canadian Medical Association Journal;8/26/2008, Vol. 179 Issue 5, p401 

    The author comments on a study by M. A. Rodger and colleagues about discontinuing anticoagulant therapy after an unprovoked venous thromboembolism. In the study, younger, nonobese women with a history of venous thromboembolism but with no signs of post-thrombotic syndrome, do not need indefinite...

  • Men had greater risk of recurrent venous thromboembolism than women. Kyrle, P. A.; Minor, E.; Bialonczyk, C. // Evidence Based Medicine;Nov/Dec2004, Vol. 9 Issue 6, p187 

    The article reports that researcher P.A. Kyrle and colleagues compared the incidence of recurrent venous thromboembolism (VTE) among men and women with incident unprovoked VTE after a mean of 8-9 months of oral anticoagulant therapy. After excluding patients with high risk thrombophilic...

  • Corrigendum to The role of novel anticoagulants in the management of venous thromboembolism.  // Vascular Medicine;Aug2014, Vol. 19 Issue 4, p337 

    The authors (Nedaa Skeik, Caleb J Murphy and Brandon R Porten) would like to highlight the following corrections to Table 2 in their review article, DOI: 10.1177/1358863X14534309. The review was printed in Vascular Medicine 2014; 19: 205–214. The authors would like to apologize for any...

  • Risk factors for thromboembolic events in patients with testicular cancer.  // British Journal of Hospital Medicine (17508460);Apr2009, Vol. 70 Issue 4, p192 

    The article examines the risk factors for thromboembolic events in patients with testicular cancer. Most thromboembolic events found are deep venous thromboses. The risk of thromboembolic events appear greatly during chemotherapy. These findings suggest the use of prophylactic anticoagulation...

  • Anticoagulant effects of Idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Harenberg, Job; Jörg, Ingrid; Vukojevic, Yvonne; Mikus, Gerd; Weiss, Christel // European Journal of Clinical Pharmacology;Jun2008, Vol. 64 Issue 6, p555 

    To gather information on anticoagulant effects after the termination of long-term therapy with idraparinux. The anticoagulant effects of idraparinux, a synthetic polymethylated analogue of its pentasaccharide, were analysed in 23 patients after termination of a 6- or 12-month therapy period for...

  • Home Treatment Versus Early Discharge From the Hospital: A Dilemma in the Management of Proximal Vein Thrombosis With Low Molecular Weight Heparins. Girolami, Antonio // Clinical & Applied Thrombosis/Hemostasis;Jan1997, Vol. 3 Issue 1, p66 

    Deals with the use of subcutaneous low molecular weight (LMW) heparin for the prophylaxis and treatment of venous thromboembolism. Efficacy and safety of hospital treatment and home treatment with LMW heparin; Analysis of the incidence of thromboembolism in hospital- and home-treated patients;...

  • Resolution of Left Atrial Thrombus after 6 Months of Anticoagulation in Candidates for Percutaneous Transvenous Mitral Commissurotomy. Silaruks, Songkwan; Kiatchoosakun, Songsak; Wongvipaporn, Chaiyasith; Tatsanavivat, Pyatat; Thinkhamrop, Bandit // Annals of Internal Medicine;1/20/2004, Vol. 140 Issue 2, p101 

    Background: Resolution of left atrial thrombus after long-term oral anticoagulation enhances safe percutaneous transvenous mitral commissurotomy (PTMC); however, the short-term benefit has not been defined. Objectives: To estimate the resolution rate of left atrial thrombus among PTMC candidates...

  • Genotype-guided warfarin dosing now a reality. Cooper-DeHoff, Rhonda M.; Pacanowski, Michael A. // Cardiology Today;Feb2008, Vol. 11 Issue 2, p18 

    The article provides information on the use of the drug warfarin. It states that the drug is the most commonly prescribed oral anticoagulant and is effective for treating thromboembolism and stroke. It is noted that optimal warfarin dosage is difficult because of its narrow therapeutic index and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics